Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates

Core Insights - Azitra, Inc. is focused on developing innovative therapies for precision dermatology, with significant advancements in its clinical pipeline during 2025 [3][8] - The company reported a net loss of $11.0 million for the year ended December 31, 2025, compared to a loss of $9.0 million in 2024, indicating ongoing investment in research and development [11] Business Highlights - In 2025, Azitra made progress in its Phase 1/2 trial for ATR-04, targeting oncology patients with EGFRi-associated rash, and successfully dosed the trial's first patient [3][5] - ATR-04 has received Fast Track designation from the FDA, addressing a significant need for approximately 150,000 patients in the U.S. affected by dermatologic toxicities from EGFR inhibitors [3][8] - The company is optimistic about its lead program, ATR-12, which is in a Phase 1b trial for Netherton syndrome, a rare disease with no known cure [3][8] - Positive preclinical data for ATR-01, targeting ichthyosis vulgaris, was presented, highlighting the potential to treat a condition affecting approximately 1.3 million people in the U.S. [3][5] Financial Overview - Research and Development (R&D) expenses for 2025 were $4.8 million, slightly up from $4.7 million in 2024, while General and Administrative (G&A) expenses decreased to $6.2 million from $6.3 million [11] - As of December 31, 2025, Azitra had cash and cash equivalents of $2.1 million, down from $4.6 million in 2024 [11][14] - The total assets of the company decreased to $5.0 million in 2025 from $7.4 million in 2024, reflecting the financial challenges faced during the year [14] Pipeline Achievements and Upcoming Milestones - The company initiated a Phase 1/2 trial for ATR-04 in Q3 2025, with topline data expected around mid-2026 [11] - Topline data from the Phase 1b trial of ATR-12 is anticipated in the second half of 2026, which could provide critical insights into its efficacy [6][11] - IND-enabling studies for ATR-01 are ongoing, with expectations for significant developments in 2026 [3][5]